PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
17.29
Current Ratio above 1.5x Drug Manufacturers - Specialty & Generic median of 2.67. Joel Greenblatt would see extra liquidity as a cushion for downturns.
15.64
Quick Ratio above 1.5x Drug Manufacturers - Specialty & Generic median of 2.13. Joel Greenblatt would see a superior short-term safety net.
13.01
Cash Ratio above 1.5x Drug Manufacturers - Specialty & Generic median of 0.96. Joel Greenblatt might see a strategic advantage in crisis periods.
-0.41
Negative interest coverage while Drug Manufacturers - Specialty & Generic median is 0.00. Seth Klarman would scrutinize earnings quality and look for debt restructuring catalysts.
No Data
No Data available this quarter, please select a different quarter.